GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda), as well as the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound), may contribute to this uncomfortable symptom through their effects on digestion
Chen BD, Zhao WC, Dong JD, Sima H
Avexitide showed significant efficacy in reducing severe hypoglycemic events in Phase 2 trials and is set to enter Phase 3 trials for PBH in early 2025 In February 2024, Eli Lilly and Company anticipated launching Mounjaro, its highly successful diabetic medication and obesity treatment, in India as early as next year if it passes an ongoing regulatory evaluation
Implications for Researchers: What This Means for Your Study So, if you're planning a study involving retatrutide, what are the practical takeaways
Different peptides serve distinct functions, which is why peptide therapy has become a growing area of interest in wellness and recovery settings